GTS Securities’s Rigel Pharmaceuticals RIGL Stock Holding History

GTS Securities’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,320	Closed	-$14.3K	–	4349
2023 Q3	$14.3K	Buy	+1,320	New	+$15.9K	﹤0.01%	3814

Other funds holding RIGL

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GTS Securities's RIGL Position: Q4 2023 in Review

GTS Securities sold out of Rigel Pharmaceuticals (RIGL) in Q4 2023, closing a stake of 1,320 shares — an estimated $14.3K sold.

GTS Securities first reported a position in RIGL in Q3 2023 and held it in 1 quarter. The position peaked at $14.3K in Q3 2023. 112 funds tracked by Wall St. Rank hold RIGL as of Q4 2023.

GTS Securities reported no remaining Rigel Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 1,320 Rigel Pharmaceuticals shares in Q4 2023, an estimated $14.3K.
GTS Securities first reported a position in Rigel Pharmaceuticals in Q3 2023 and held it in 1 quarter.
GTS Securities's Rigel Pharmaceuticals position peaked at $14.3K in Q3 2023.
112 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.